Review decision – November 2018

Decision to re-issue the guidance and move it to the static list

We would like to update you on the decision made regarding the review of the existing guidance on TA293; Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura and TA221; Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura.

The marketing authorisations for both romiplostim and eltrombopag have been extended to include patients who have not had splenectomy, and children. The change with respect to prior splenectomy can be addressed by an amendment to the recommendation wording.

No other new evidence has been identified that could be expected to lead to a change in the recommendations.

NICE’s Guidance Executive has decided to proceed with this proposal without consultation.

Consequently, the wording of the guidance for both TA293 and TA221 has been amended and both TA293 and TA221 have been re-issued. The re-issued guidance will be transferred to the technology appraisals ‘static list’.

Review decision paper

Matrix of stakeholders


This page was last updated: 09 November 2018